Ask AI
ProCE Banner Activity

CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs Sunitinib Alone in Patients With Metastatic Renal Cell Carcinoma

Conference Coverage
Slideset
Final analysis showed survival with sunitinib alone not inferior to nephrectomy followed by sunitinib.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech

Janssen

Merck Oncology

Seagen